Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(409)
•••
Comment by bringon10baggeron Aug 25, 2019 11:24am
157 Views
Post# 30063633

RE:RE:British Journal say 12!,!,

RE:RE:British Journal say 12!,!,I'm with you DH22, not a big issue with 1 or 2 dozen participants, just referring to Nov 27 PR from DL, my thoughts Dr. W has all bases covered off and they know completely the expected results and just going through the red tape for authoratative approvals. I've been in this for 4 patient years and have complete confidence in the mgmt team, always ttransparent and doing what it takes to be the GAME CHANGER of NSAID's, There have been some curve balls along the way but they are ensuring they are covering all bases,   and IMHO they are rounding third base now and heading for home..................GO TEAM GO!..........
duckhead22 wrote: 12 or 24? Do you really think management would go forward with large dosing trial, if they were not about 99% sure. Do not have any background to compare what the typical small tests like that are supposed to  be, but repeat again naproxin works and thats what they are using as the base compound.  I would have much more trepidation if this was a totally new drug.  BP would not be in data room now if they did not expect to be successful as well.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities